Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budenofalk for induction of remission in incomplete microscopic colitis
2013-001912-31Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Nov 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in microscopic colitis (MC) comparing Budenofalk 9 mg with Placebo (2 arms). Primary endpoint: Clinical remission at final/withdrawal visit. Started Nov 2013; status: completed.
02
Drugs
budesonide
03
Conditions
microscopic colitis (MC)
Beyond the preview
Go deeper on 2013-001912-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001912-31.